RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Brazil: Anvisa Publishes New Reference Product Proposal

Brazil: Anvisa Publishes New Reference Product Proposal

Posted 25 June 2012 | By Ansis Helmanis

Brazil's National Health Surveillance Agency (ANVISA) published a new proposed rule on medicines used as reference products for generic equivalents (RDC No. 35/12) on 19 June 2012.

According to the proposal, the List of Reference Medicines shall consist of three groups of drugs: 

  • Group A for medicines that contain only one active pharmaceutical ingredient;
  • Group B for medicines that contain two or more active ingredients in a single dosage form; and
  • Group C for products containing two or more active ingredients in the same or different dosage forms. 

Drugs that have been withdrawn from the market or have safety, efficacy or quality concerns will be excluded from the List.

Read more:

RDC No. 35/12

More Breaking News from RegLink


© 2022 Regulatory Affairs Professionals Society.